A New Spin on Antibody Drug Conjugates: Trastuzumab-Fulvestrant Colloidal Drug Aggregates Target HER2-Positive Cells
A New Spin on Antibody Drug Conjugates: Trastuzumab-Fulvestrant Colloidal Drug Aggregates Target HER2-Positive Cells
复制标题
DOI：
10.1021/acsami.6b15987
复制
发表时间：
2017-04-12
影响因子：
9.5
通讯作者：
Shoichet, Molly S.
中科院分区：
文献类型：
--
作者：
Ganesh, Ahil N.;McLaughlin, Christoiher K.;Shoichet, Molly S.
虽然胶体聚集体的形成导致早期药物发现中的伪像，但它们的组成使它们作为用于靶向药物递送的纳米颗粒制剂具有吸引力，因为整个纳米颗粒由药物组成。胶体聚集体的典型瞬时稳定性抑制了利用这种性质。为了克服这一限制，我们研究了一系列蛋白质来稳定化学治疗剂氟维司群的胶体聚集体，包括以下：牛血清白蛋白，一种通用的人免疫球蛋白G，和曲妥珠单抗，一种治疗性人表皮生长因子受体2抗体。蛋白质冠减少胶体大小，
While the formation of colloidal aggregates leads to artifacts in early drug discovery, their composition makes them attractive as nanoparticle formulations for targeted drug delivery as the entire nanoparticle is composed of drug. The typical transient stability of colloidal aggregates has inhibited exploiting this property. To overcome this limitation, we investigated a series of proteins to stabilize colloidal aggregates of the chemotherapeutic, fulvestrant, including the following: bovine serum albumin, a generic human immunoglobulin G, and trastuzumab, a therapeutic human epidermal growth factor receptor 2 antibody. Protein coronas reduced colloid size to